Ranked by reported Q1 2026 13F market value
Share of total reported institutional value in DRUG held by the largest 10 / 25 filers.
| # | Institution | Shares Held | Market Value | QoQ Change | Ownership % | % of Fund |
|---|---|---|---|---|---|---|
| 1 | JANUS HENDERSON GROUP PLC | 1.3M | $93.5M | +11.1% | 16.547% | 0.05% |
| 2 | Cormorant Asset Management, LP | 1.1M | $77.3M | 0.0% | 13.649% | 3.88% |
| 3 | BlackRock, Inc. | 622K | $45.4M | +57.8% | 8.013% | 0.00% |
| 4 | Vivo Capital, LLC | 557K | $40.7M | +11.1% | 7.179% | 3.39% |
| 5 | BRAIDWELL LP | 540K | $39.4M | +66.4% | 6.954% | 1.31% |
| 6 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 496K | $36.2M | +25.3% | 6.387% | 0.06% |
| 7 | Vestal Point Capital, LP | 492K | $35.9M | — | 6.343% | 1.00% |
| 8 | DRIEHAUS CAPITAL MANAGEMENT LLC | 433K | $31.6M | +60.4% | 5.573% | 0.23% |
| 9 | PERCEPTIVE ADVISORS LLC | 378K | $27.5M | -16.0% | 4.864% | 0.54% |
| 10 | BALYASNY ASSET MANAGEMENT LLC | 297K | $21.7M | +31.8% | 3.829% | 0.07% |
| 11 | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 283K | $20.7M | — | 3.646% | 0.24% |
| 12 | RA CAPITAL MANAGEMENT, L.P. | 265K | $19.3M | — | 3.414% | 0.20% |
| 13 | GREAT POINT PARTNERS LLC | 220K | $16.1M | — | 2.834% | 3.93% |
| 14 | MPM Oncology Impact Management LP | 212K | $15.5M | -7.8% | 2.734% | 1.20% |
| 15 | Ikarian Capital, LLC | 167K | $12.2M | +4.5% | 2.147% | 1.29% |
| 16 | WELLINGTON MANAGEMENT GROUP LLP | 137K | $10.0M | +898.5% | 1.761% | 0.00% |
| 17 | MORGAN STANLEY | 133K | $9.7M | +0.5% | 1.710% | 0.00% |
| 18 | EVENTIDE ASSET MANAGEMENT, LLC | 130K | $9.5M | +26.2% | 1.675% | 0.16% |
| 19 | SEVEN GRAND MANAGERS, LLC | 120K | $8.8M | +140.0% | 1.546% | 0.59% |
| 20 | ACUTA CAPITAL PARTNERS, LLC | 112K | $8.2M | +32.6% | 1.443% | 5.88% |
| 21 | STATE STREET CORP | 108K | $7.9M | +40.1% | 1.395% | 0.00% |
| 22 | GEODE CAPITAL MANAGEMENT, LLC | 89K | $6.5M | +39.6% | 1.143% | 0.00% |
| 23 | Sio Capital Management, LLC | 86K | $6.3M | +5.1% | 1.109% | 0.91% |
| 24 | GOLDMAN SACHS GROUP INC | 74K | $5.4M | +53.2% | 0.958% | 0.00% |
| 25 | B Group, Inc. | 68K | $4.9M | — | 0.870% | 3.65% |
denotes a marquee investor (Buffett, Burry, ARK, Tiger Global, Pershing Square, Baupost and other widely-followed managers). “% of Fund” shows how much of that investor’s total 13F portfolio is invested in DRUG — a direct measure of their conviction.
Filings activity in DRUG during Q1 2026, grouped by how each filer changed its position.
8 quarters of 13F filings · Δ columns show change vs prior quarter
| Quarter | Inst. Holders | Δ Holders | Ownership % | Δ Ownership | Total 13F Value | Δ Value |
|---|---|---|---|---|---|---|
| Q1 2026 | 92 | +24% | 141.50% | +32.75 pp | $669M | +30% |
| Q4 2025 | 74 | +17% | 108.75% | +31.45 pp | $514M | +41% |
| Q3 2025 | 63 | +29% | 77.30% | +48.41 pp | $366M | +168% |
| Q2 2025 | 49 | +40% | 28.89% | 10.82 pp | $137M | 27% |
| Q1 2025 | 35 | +13% | 39.71% | +2.42 pp | $188M | +6.5% |
| Q4 2024 | 31 | +343% | 37.29% | +37.24 pp | $176M | +76659% |
| Q3 2024 | 7 | +0.0% | 0.05% | +0.01 pp | $0M | +10% |
| Q2 2024 | 7 | — | 0.04% | — | $0M | — |
Source: SEC 13F institutional filings. Ownership % requires market cap data and will show once linked. Δ columns compare to the immediately prior filed quarter.
Quick answers to the most common questions about buying DRUG stock.
Based on Q1 2026 13F filings, institutional ownership of Bright Minds Biosciences Inc. stands at 141.5%, held across 92 reporting institutions.
JANUS HENDERSON GROUP PLC is the largest reported institutional holder of DRUG, with approximately 1,284,324 shares worth $0.09B as of Q1 2026.
No marquee "smart money" managers (Berkshire, Burry, ARK, Tiger Global, Pershing Square, Baupost, etc.) currently appear among the top 25 institutional holders of DRUG.
Our composite Smart Money Score for DRUG is 54 out of 100 (Neutral). It combines net institutional buying activity, ownership shift, marquee investor presence, and holder-count growth.
29 institutions opened new positions in DRUG during Q1 2026, while 11 fully exited. 40 added to existing positions and 23 trimmed.
DRUG institutional ownership rose by 32.75 percentage points quarter-over-quarter, with a net change of +18 holders.
The top 10 institutions account for 67.1% of all reported 13F value in DRUG, and the top 25 account for 91.1%.
All data is sourced from SEC Form 13F filings, which institutional investment managers with at least $100M in assets are required to file each quarter. We process every 13F filing from EDGAR and recompute the aggregates after each cycle. Insider transactions are sourced from Form 4 filings.
Bright Minds Biosciences Inc. (DRUG) Institutional Ownership